NCT03688139Completed
Reward Function and Therapy for Late-Life Depression
Positive Valence System Function and Reward Exposure Therapy for Late-Life Depression
Source: ClinicalTrials.gov · Last updated 14 Nov 2024
Brief summary (registry, in English)
The goal of this study is to learn about changes in the brain that occur during Engage, a psychotherapy for depression in older adults, and how they may differ from changes that occur during supportive therapy. Older adults with depression will receive 9 weeks of either Engage or supportive therapy and will complete research assessments before the therapy begins and at weeks 3, 6, and 9 of treatment. Research assessments will include questionnaires, computer tasks, and recordings of electrical brain activity (also called electroencephalography or EEG).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 26 Sept 2018
- Start date
- 14 Mar 2019
- Primary completion date
- 18 Jan 2024
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Depression
- NCT number
- NCT03688139
What you commit to
- Study type: Interventional
- Participants enrolled: 65
- From 14 Mar 2019 to the primary completion date, 18 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of psychotropic drugs or cholinesterase inhibitors other than use of less than or equal to 0.5 mg of lorazepam daily up to five times per week.
Other illness
- Presence of current psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, or specific phobia.
- History of past psychiatric diagnoses other than major depressive disorder without psychotic features or anxiety disorders (separation anxiety disorder, specific phobia, social phobia, panic disorder, agoraphobia, or generalized anxiety disorder).
- Neurological disorders (dementias, history of stroke, multiple sclerosis, Parkinson's disease, epilepsy, etc.); cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease; metastatic cancer; or debilitated states or less common medical illnesses that may either influence neural systems of interest or ability to participate in the study.
Other
- Intent or plan to attempt suicide in the near future.
Who the study is looking for
- Age greater than or equal to 60 years.
- Diagnosis of unipolar major depressive disorder without psychotic features, determined by Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID).
- Montgomery-Asberg Depression Rating Scale (MADRS) score greater than or equal to 20.
- Mini Mental State Exam (MMSE) score greater than or equal to 24.
- Off antidepressants or on a stable dose of an antidepressant for 12 weeks and no intent to change the dose in the next 10 weeks.
- Capacity to provide written consent for both research assessment and treatment.
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine Coordinator of this site? Confirm its status | White Plains | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.